Product Information
DABIGATRAN ETEXILATE 110 MG CP is a generic product labeled by Aurobindo Pharma Limited, priced at $0.9198 per EA under NDC 59651097460. Its NADAC has been published 28 times since Dec 17, 2025.
Strength
110 mg/1
Manufacturer
Aurobindo Pharma LimitedNDC
59651097460
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Last Updated
6/17/2026
Active Ingredients
DABIGATRAN ETEXILATE MESYLATEApproval Type
Generic (ANDA)
FDA Application
ANDA208039On Market Since
5/14/2025
Pharmacological Classes
Price Statistics
The NADAC for DABIGATRAN ETEXILATE 110 MG CP has been published 28 times since Dec 17, 2025, and over the history we have for it it has declined 34.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.9198 per EA |
|---|---|
| All-time high | $1.4058 (Jan 14, 2026) |
| All-time low | $0.9196 (May 20, 2026) |
| 52-week high | $1.4058 |
| 52-week low | $0.9196 |
| Median price | $1.0186 |
| Average price | $1.1030 |
| Largest weekly change | -11.9% (Feb 18, 2026) |
| Weeks tracked | 28 |
| Tracking since | Dec 17, 2025 |
Generic Alternatives
The matcher finds 1 NADAC-published product sharing this drug's active ingredient, strength, and dosage form across 1 manufacturer (up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of DABIGATRAN ETEXILATE 110 MG CP?
The current National Average Drug Acquisition Cost (NADAC) for DABIGATRAN ETEXILATE 110 MG CP, manufactured by Aurobindo Pharma Limited, is $0.9198 per EA (NDC 59651097460), effective Jun 24, 2026.
How has the price of DABIGATRAN ETEXILATE 110 MG CP changed over time?
Over the history we have for it, the NADAC for DABIGATRAN ETEXILATE 110 MG CP has declined 34.6%. It has been tracked across 28 weekly CMS publications since Dec 17, 2025.
What are the highest and lowest recorded NADAC prices for DABIGATRAN ETEXILATE 110 MG CP?
Since Dec 17, 2025, the NADAC for DABIGATRAN ETEXILATE 110 MG CP has ranged from a low of $0.9196 (May 20, 2026) to a high of $1.4058 (Jan 14, 2026), with a median of $1.0186 per EA.
Are there cheaper alternatives to DABIGATRAN ETEXILATE 110 MG CP?
1 NADAC-published product shares the same active ingredient, strength, and dosage form as DABIGATRAN ETEXILATE 110 MG CP, but none are currently priced below it.
Who manufactures DABIGATRAN ETEXILATE 110 MG CP?
DABIGATRAN ETEXILATE 110 MG CP (NDC 59651097460) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.
Related Drugs
Same classification